PURPOSE: In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of thenonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non-cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss. PATIENTS AND METHODS: We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease-free survival, incidence of contralateral new primary breast cancer, and safety. RESULTS: In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease-free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms. CONCLUSION: This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-positive breast cancer.
RCT Entities:
PURPOSE: In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non-cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss. PATIENTS AND METHODS: We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease-free survival, incidence of contralateral new primary breast cancer, and safety. RESULTS: In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease-free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms. CONCLUSION: This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-positive breast cancer.
Authors: Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch Journal: N Engl J Med Date: 2005-12-29 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: D C Johannessen; T Engan; E Di Salle; M G Zurlo; J Paolini; G Ornati; G Piscitelli; S Kvinnsland; P E Lonning Journal: Clin Cancer Res Date: 1997-07 Impact factor: 12.531
Authors: Paul E Goss; Peyman Hadji; Milayna Subar; Paula Abreu; Torben Thomsen; Jose Banke-Bochita Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Judith-Anne W Chapman; Joseph P Costantino; Bin Dong; Richard G Margolese; Kathleen I Pritchard; Lois E Shepherd; Karen A Gelmon; Norman Wolmark; Michael N Pollak Journal: Breast Cancer Res Treat Date: 2015-08-15 Impact factor: 4.872
Authors: Kathrin Strasser-Weippl; Michaela J Higgins; Judith-Anne W Chapman; James N Ingle; George W Sledge; George T Budd; Matthew J Ellis; Kathleen I Pritchard; Mark J Clemons; Tanja Badovinac-Crnjevic; Lei Han; Karen A Gelmon; Manuela Rabaglio; Catherine Elliott; Lois E Shepherd; Paul E Goss Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506
Authors: James N Ingle; Fang Xie; Matthew J Ellis; Paul E Goss; Lois E Shepherd; Judith-Anne W Chapman; Bingshu E Chen; Michiaki Kubo; Yoichi Furukawa; Yukihide Momozawa; Vered Stearns; Kathleen I Pritchard; Poulami Barman; Erin E Carlson; Matthew P Goetz; Richard M Weinshilboum; Krishna R Kalari; Liewei Wang Journal: Cancer Res Date: 2016-10-10 Impact factor: 12.701
Authors: Judy-Anne W Chapman; Kathleen I Pritchard; Paul E Goss; James N Ingle; Hyman B Muss; Susan F Dent; Ted A Vandenberg; Brian Findlay; Karen A Gelmon; Carolyn F Wilson; Lois E Shepherd; Michael N Pollak Journal: World J Clin Oncol Date: 2014-12-10
Authors: James N Ingle; Junmei Cairns; Vera J Suman; Lois E Shepherd; Peter A Fasching; Tanya L Hoskin; Ravinder J Singh; Zeruesenay Desta; Krishna R Kalari; Matthew J Ellis; Paul E Goss; Bingshu E Chen; Bernhard Volz; Poulami Barman; Erin E Carlson; Tufia Haddad; Matthew P Goetz; Barbara Goodnature; Matthew E Cuellar; Michael A Walters; Cristina Correia; Scott H Kaufmann; Richard M Weinshilboum; Liewei Wang Journal: Clin Cancer Res Date: 2020-02-25 Impact factor: 12.531
Authors: Jason D Robarge; Zereunesay Desta; Anne T Nguyen; Lang Li; Daniel Hertz; James M Rae; Daniel F Hayes; Anna M Storniolo; Vered Stearns; David A Flockhart; Todd C Skaar; N Lynn Henry Journal: Breast Cancer Res Treat Date: 2016-12-09 Impact factor: 4.872